血流性休克创伤患者的前环素:一个随机临床试验
Pär I Johansson1, Christian Fenger Eriksen, Pernille E Bovbjerg
1From the CAG Center for Endotheliomics (P.I.J.), Copenhagen University Hospital-Rigshospitalet; Department of Clinical Medicine (P.I.J.), University of Copenhagen, Copenhagen; Department of Anesthesiology (C.F.E., M.S.A.), Aarhus University Hospital, Aarhus; Department of Orthopedic Surgery (P.E.B.), Odense University Hospital, Odense, Denmark; Department of Traumatology (C.G., P.A.N.), Oslo University Hospital; Institute of Clinical Medicine (C.G., P.A.N.), University of Oslo, Oslo, Norway; Department of Anesthesiology (M.P.) and Intensive Care V (M.P.), Odense University Hospital, Odense; CAG Center for Endotheliomics (H.H.H., K.H.P., M.V.), Copenhagen University Hospital-Rigshospitalet; Section of Biostatistics (T.L.), University of Copenhagen, Copenhagen; Research Center for Emergency Medicine (H.K.), Aarhus University Hospital; Aarhus University (H.K.), Aarhus; and CAG Center for Endotheliomics (J.S.), and Department of Anesthesiology (J.S.), Department of Anesthesiology, Centre of Head and Orthopedics (J.S.), Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
伊洛普罗斯特并没有改善重症监护室 (ICU) 无创伤患者患有出血性休克的无重症监护室 (ICU) 日. 然而,这种前环素类似物是安全的,并显著减少了住院时间,这需要进一步研究.
科学领域:
- 创伤重症监护中心的重症监护中心.
- 内皮功能和内皮功能障碍
- 药理干预在冲击中的药理干预.
背景情况:
- 多器官衰竭是创伤患者的主要死亡原因之一,内皮质病症发挥着重要作用.
- 试点研究表明,前环素类似物可以改善重症患者的内皮功能.
- 这项研究调查了伊洛普罗斯特在创伤患者患有出血性休克时改善结果的潜力.
研究的目的:
- 评估伊洛普罗斯特输液在改善创伤患者经历出血性休克的治疗结果方面的疗效.
- 为了确定伊洛普罗斯特是否会增加28天内生命中没有重症监护室 (ICU) 的天数.
- 评估伊洛普罗斯特对28天死亡率和住院时间的安全性和影响.
主要方法:
- 一个多中心的,随机的,盲目的临床试验,涉及229名创伤患者出血性休克.
- 患者接受了72小时的伊洛普罗斯特 (1 ng/kg/min) 或安慰剂输注.
- 主要结局:28天内没有接受ICU治疗的活期;次要结局:28天死亡率和住院时间.
主要成果:
- 伊洛普罗斯特治疗并没有导致无ICU日数在统计上显著增加 (15.64 vs 13.99天; p=0.28).
- 在伊洛普罗斯特和安慰剂组之间28天全因死亡率没有显著差异 (18.8%与19.6%;p=0.97).
- 在伊洛普罗斯特组中观察到住院时间的统计显著减少 (平均差异为7.84天;p=0.01).
结论:
- 伊洛普罗斯特在创伤患者和出血性休克患者中是安全的.
- 虽然伊洛普罗斯并没有改善无ICU日,但显著减少了住院时间.
- 建议进一步调查前环素在治疗休克创伤患者中的作用.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...


